arrow
返回

Stemness in solid malignancies: coping with immune attack

delete2024-10-25
delete1
PRE
AI
J
Judith Agudo *
Y
Yuxuan Miao *
DOI:10.1038/s41568-024-00760-0delete
delete原文链接
delete分享
delete收藏
摘要

摘要

En 中文
Immunotherapy has become a key new pillar of cancer treatment, and this has sparked interest in understanding mechanisms of cancer immune evasion. It has long been appreciated that cancers are constituted by heterogeneous populations of tumour cells. This feature is often fuelled by specialized cells that have molecular programs resembling tissue stem cells. Although these cancer stem cells (CSCs) have capacity for unlimited self-renewal and differentiation, it is increasingly evident that some CSCs are capable of achieving remarkable immune resistance. Given that most immunotherapy regiments have overlooked CSC-specific immune-evasive mechanisms, many current treatment strategies often lead to cancer relapse. This Review focuses on advancements in understanding how CSCs in solid tumours achieve their unique immune-evasive properties, enabling them to drive tumour regrowth. Moreover, as cancers often arise from tissue stem cells that acquired oncogenic mutations, we discuss how tissue stem cells undergoing malignant transformation activate intrinsic immune-evasive mechanisms and establish close interactions with suppressive immune cells to escape immune surveillance. In addition, we summarize how in advanced disease stages, CSCs often hijack features of normal stem cells to resist antitumour immunity. Finally, we provide insights in how to design a new generation of cancer immunotherapies to ensure elimination of CSCs. Immunotherapy shows promise in treating cancers by engineering T cells or using antibodies to activate them. However, cancer stem cells (CSCs) resist immunotherapies and drive cancer relapse. In this Review, Agudo and Miao highlight the mechanisms through which normal stem cells and CSCs in solid tumours achieve immune resistance, offering insights for the development of more effective cancer treatments.
Keyword:
TUMOR-INITIATING CELLS
T-CELLS
CANCER-IMMUNOTHERAPY
INFLAMMATORY MEMORY
SUPPRESSOR-CELLS
WOUND REPAIR
MOUSE
METASTASIS
EXPRESSION
GROWTH

期刊

Nature Reviews Cancer 封面图
Nature Reviews Cancer
IF:
66.8
论文数:
3.8K
被引数:
7.9W

机构

D
Dana-Farber Cancer Institute
学者数:
1.5K
论文数: 386
被引数: 1.3W
H
Harvard University
学者数:
7.3K
论文数: 2.5K
被引数: 20.7W
引用论文

引用论文

err分享
err收藏
Wireless Communications Security
err
IF0
err2016-10-07
err0
PREAI
errJyrki T. J. Penttinen
err分享
err收藏
Quiescent Tissue Stem Cells Evade Immune Surveillance静止的组织干细胞逃避免疫监视
errIMMUNITY
IF26.3
err2018-02-01
err183
errOAAI
errAgudo, Judith; Park, Eun Sook; Rose, Samuel A.; Alibo, Eziwoma; Sweeney, Robert; Dhainaut, Maxime; Kobayashi, Koichi S.; Sachidanandam, Ravi; Baccarini, Alessia; Merad, Miriam; Brown, Brian D.
err分享
err收藏
err分享
err收藏
Glioblastoma Cancer Stem Cells Evade Innate Immune Suppression of Self-Renewal through Reduced TLR4 Expression
err2017-04-01
err149
errOAAI
errAlvarado, Alvaro G.; Thiagarajan, Praveena S.; Mulkearns-Hubert, Erin E.; Silver, Daniel J.; Hale, James S.; Alban, Tyler J.; Turaga, Soumya M.; Jarrar, Awad; Reizes, Ofer; Longworth, Michelle S.; Vogelbaum, Michael A.; Lathia, Justin D.
err分享
err收藏
Hallmarks of cancer stemness癌症stemness的标志
err2024-05-01
err11
PREAI
errLoh, Jia-Jian; Ma, Stephanie
err分享
err收藏
Cancer Stem Cell-Secreted Macrophage Migration Inhibitory Factor Stimulates Myeloid Derived Suppressor Cell Function and Facilitates Glioblastoma Immune Evasion
err2016-05-27
err201
errOAAI
errOtvos, Balint; Silver, Daniel J.; Mulkearns-Hubert, Erin E.; Alvarado, Alvaro G.; Turaga, Soumya M.; Sorensen, Mia D.; Rayman, Patricia; Flavahan, William A.; Hale, James S.; Stoltz, Kevin; Sinyuk, Maksim; Wu, Qiulian; Jarrar, Awad; Kim, Sung-Hak; Fox, Paul L.; Nakano, Ichiro; Rich, Jeremy N.; Ransohoff, Richard M.; Finke, James; Kristensen, Bjarne W.; Vogelbaum, Michael A.; Lathia, Justin D.
err分享
err收藏
学者 查看更多内容